SLDB vs. ANNX, KROS, MREO, RAPP, DNA, TRDA, ORKA, TRML, XERS, and ALT
Should you be buying Solid Biosciences stock or one of its competitors? The main competitors of Solid Biosciences include Annexon (ANNX), Keros Therapeutics (KROS), Mereo BioPharma Group (MREO), Rapport Therapeutics (RAPP), Ginkgo Bioworks (DNA), Entrada Therapeutics (TRDA), Oruka Therapeutics (ORKA), Tourmaline Bio (TRML), Xeris Biopharma (XERS), and Altimmune (ALT). These companies are all part of the "pharmaceutical products" industry.
Solid Biosciences vs.
Annexon (NASDAQ:ANNX) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, community ranking, analyst recommendations and institutional ownership.
Solid Biosciences received 217 more outperform votes than Annexon when rated by MarketBeat users. However, 77.14% of users gave Annexon an outperform vote while only 68.96% of users gave Solid Biosciences an outperform vote.
In the previous week, Solid Biosciences had 4 more articles in the media than Annexon. MarketBeat recorded 12 mentions for Solid Biosciences and 8 mentions for Annexon. Annexon's average media sentiment score of 0.78 beat Solid Biosciences' score of 0.44 indicating that Annexon is being referred to more favorably in the media.
Solid Biosciences has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.
Annexon currently has a consensus target price of $15.80, indicating a potential upside of 276.19%. Solid Biosciences has a consensus target price of $15.30, indicating a potential upside of 367.89%. Given Solid Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Solid Biosciences is more favorable than Annexon.
81.5% of Solid Biosciences shares are owned by institutional investors. 12.7% of Annexon shares are owned by company insiders. Comparatively, 13.6% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Annexon has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500.
Annexon's return on equity of -38.99% beat Solid Biosciences' return on equity.
Summary
Solid Biosciences beats Annexon on 12 of the 17 factors compared between the two stocks.
Get Solid Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Solid Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:SLDB) was last updated on 1/18/2025 by MarketBeat.com Staff
Free SLDB Stock Alerts